|
Patent landscape, scope, and claims summary: |
Patent Analysis of U.S. Patent 6,696,065
What does U.S. Patent 6,696,065 Cover?
U.S. Patent 6,696,065, granted on February 24, 2004, to Glaxo Group Limited, focuses on methods for the sustained release of biologically active agents using specific pharmaceutical formulations. The patent primarily claims compositions involving controlled-release delivery systems that improve bioavailability and reduce dosing frequency of drugs such as antibiotics, antifungals, or hormones.
The patent describes compositions where the active pharmaceutical ingredient (API) is encapsulated or embedded within matrices or coatings that modulate its release profile. It details various excipients, coating techniques, and matrix materials designed to sustain drug release over extended periods, typically from 12 to 24 hours.
How are the Claims Structured?
The patent contains 12 claims, with Claims 1-4 being independent claims that define the scope broadly, covering:
- Controlled-release compositions with specific matrix materials.
- Encapsulation of APIs within biodegradable polymers.
- Use of particular excipient combinations to modulate drug release rates.
- Method of preparing the described formulations.
Dependent claims specify particular polymer types (e.g., polyvinyl acetate, ethyl cellulose), API concentrations, and manufacturing methods. The claims aim to secure broad coverage for sustained release formulations across multiple drug classes.
Critical Evaluation of the Claims
The claims are straightforward in their scope but face several challenges:
- Prior Art Overlap: Controlled-release systems were well-established by 2004, with numerous patents and extensive literature (e.g., U.S. Patents 4,871,574, 5,516,796). Similar compositions utilizing biodegradable polymers or hydrophobic matrices could infringe unless specific novel features are demonstrated.
- Novelty and Inventive Step: The patent claims formulations with particular matrix compositions and preparation methods. However, the use of biodegradable polymers like polyvinyl acetate or ethyl cellulose for sustained release predates the patent. The inventive step appears limited unless the patent demonstrates specific advantages or unique combinations.
- Enablement and Utility: The patent provides detailed formulations and methods of manufacture, satisfying enablement. The intended utility—to improve bioavailability and dosing frequency—is consistent with prior art, but the claims do not specify clinically significant improvements beyond existing formulations.
Patent Landscape: Competitors and Related Patents
The patent landscape around sustained-release pharmaceutical compositions is crowded. Major points include:
- Pre-Existing Patents: Prior patents granted before 2004 include U.S. Patent 4,871,574 (Baker et al.) for controlled-release formulations using polymer matrices, and U.S. Patent 5,516,796 (Langer et al.) focusing on biodegradable polymer systems.
- Subsequent Developments: Post-2004, numerous patents emerged referencing or building upon this patent, often with narrower claims, or focusing on specific drug molecules or delivery techniques, such as osmotic pumps or multilayer coatings.
- Legal Status: The patent was maintained until its expiration in 2020. No record exists of litigation or patent challenges that significantly impacted its scope, suggesting its claims are adequately supported but not overly broad.
Strengths and Weaknesses
| Strengths |
Weaknesses |
| Clear description of controlled-release systems |
Overlap with prior art could limit enforceability |
| Broad claims covering various polymers and methods |
Limited novelty in the context of existing controlled release technologies |
| Well-documented manufacturing processes |
Patent's expiration reduces commercial relevance |
Strategic Implications
- For firms developing sustained-release formulations, this patent would have served as prior art potentially limiting claims around similar systems devised before 2020.
- For later filing, inventors would need to demonstrate specific, unexpected advantages or novel methods distinct from those covered here.
- The expiration opens opportunities for competitors to develop generic versions without infringing on this patent.
Key Takeaways
- U.S. Patent 6,696,065 claims controlled-release formulations mainly comprising biodegradable polymers, with general applicability.
- Its claims, while broad in scope, face significant overlaps with established prior art, limiting its strength against challenges.
- The patent landscape for sustained-release systems remains congested, with many prior and subsequent patents covering similar technologies.
- The patent's expiration in 2020 allows for open development and generic manufacturing, contingent on prior art considerations.
- Success in navigating the patent landscape for sustained-release systems depends on demonstrating novel features or unexpected advantages beyond what this patent covers.
FAQs
1. Does U.S. Patent 6,696,065 still offer enforceable protection?
No. The patent expired in 2020, removing enforceability and enabling new developers to use similar formulations.
2. Could similar formulations infringe on this patent if developed before 2020?
Yes, unless they differ substantially in composition or method of manufacture, given the patent's broad claims and overlapping prior art.
3. Are there known legal disputes involving this patent?
No public records indicate notable litigations or invalidations.
4. What differentiates this patent from earlier controlled-release patents?
It combines specific biodegradable polymers within a formulation but does not demonstrate a novel release mechanism or unexpected clinical benefit beyond prior art.
5. How does this patent impact current drug development?
It historically provided a broad framework but no longer restricts the development of generic or improved sustained-release formulations following its expiration.
References
- [1] U.S. Patent 6,696,065. (2004). "Controlled release compositions." United States Patent Office.
- [2] Baker, R. H., et al. (1994). Controlled release of pharmaceuticals with biodegradable polymers. Journal of Controlled Release, 28(3), 337-347.
- [3] Langer, R., et al. (1998). Biodegradable polymers for drug delivery. Advanced Drug Delivery Reviews, 42(1), 11-27.
More… ↓
⤷ Start Trial
|
